Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Brazzein, now FDA-approved, emerges as a zero-calorie sweetener potentially safe for diabetic and obese populations, requiring further study to validate its health impacts.
Cardiology May 17th 2024
Medical Professionals Reference (MPR)
Explore the FDA-cleared Modius Stress, offering groundbreaking ease in managing generalized anxiety with daily 30-minute sessions, showing significant reductions in GAD-7 scores in international clinical trials.
Psychiatry May 14th 2024
Oncology News Central (ONC)
Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.
Oncology, Medical May 13th 2024
Psych Congress Network
Rejoyn represents a significant advancement in the treatment of major depressive disorder, requiring prescription use and integrating brain-training exercises developed by leading mental health experts.
Psychiatry May 7th 2024
MedTech Dive
The recent FDA approval of Lumicell’s breast cancer imaging system introduces a novel intraoperative tool that significantly enhances the precision of tumor resections, potentially reducing the need for subsequent corrective surgeries.
Oncology, Surgical April 22nd 2024
Zevtera® (ceftobiprole medocaril) provides a significant advancement in treating serious bacterial infections, demonstrating high efficacy against both MRSA and MSSA in recent phase 3 clinical trials.
Infectious Diseases April 18th 2024